News &amp; Updates

A recent study has demonstrated the effectiveness of a structured paediatric-adult dyad transition care model in encouraging prompt initial attendance and ensuring continuity of care for patients with childhood-onset systemic lupus erythematosus (cSLE) during the critical transition from paediatric to adult healthcare.

Transition model eases move from paediatric to adult care for cSLE patients

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

11 Dec 2025

Persistent binge drinking tied to advanced fibrosis, death in MetALD

In patients with metabolic dysfunction and alcohol-related liver disease (MetALD), persistent binge drinking history is a risk factor for advanced fibrosis and mortality, according to a study.

Persistent binge drinking tied to advanced fibrosis, death in MetALD

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

The treatment landscape for EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) is rapidly evolving, with many exciting developments on the horizon. At a recent scientific symposium, experts in lung cancer gathered to review the latest advances. This article highlights the key takeaways from the symposium, summarizing FLAURA2 trial data presented by Professor Natalia Valdiviezo from San Ignacio de Loyola University, Lima, Peru, and main insights from the panel discussion led by Dr Herbert Loong from the Department of Clinical Oncology, the Chinese University of Hong Kong, with contributions from Dr James Ho of the Department of Medicine, University of Hong Kong, and Dr Michael Kam, Specialist in Clinical Oncology in Hong Kong.

Osimertinib plus chemo-therapy: A promising 1L option for high-risk EGFRm NSCLC

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

A 70-year-old male was diagnosed with prostate cancer (PC) after presenting with increased urinary frequency and an elevated prostate-specific antigen (PSA) level of 71 ng/mL in October 2022. (Figure) MRI revealed a 3 cm left prostatic lesion without pelvic lymph node involvement or bone metastases, with possible extraprostatic extension and seminal vesicle invasion. Transperineal ultrasound-guided prostate biopsy confirmed prostatic adenocarcinoma in 8 out of 12 cores, with a Gleason score of 4 + 3.

Achieving ultra-low PSA levels with ADT plus ARPI improves mHSPC outcomes in a patient with comorbidities

11 Dec 2025

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and historically poor outcomes. Prior to the emergence of antibody–drug conjugates (ADCs), palliative sequential single-agent chemotherapy was the mainstay of treatment for metastatic TNBC (mTNBC), offering limited response and survival. In an interview with MIMS Oncology, Dr Rodrigo Sánchez-Bayona from the Universitary Hospital 12 de Octubre, Madrid, Spain, discussed how Trop-2–targeted ADCs have changed the treatment landscape of mTNBC and predicted their future role in the changing treatment paradigm. He highlighted data on sacituzumab govitecan (SG), an ADC that has demonstrated efficacy regardless of Trop-2 expression status or presence of biomarkers while maintaining quality of life (QoL), and shared a patient case with rapidly progressing mTNBC effectively treated with SG.

Addressing unmet needs in mTNBC: Insights on Trop-2–directed ADCs

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

Management of X-linked hypophosphataemia (XLH) has evolved in the past few years following the availability of burosumab, a fully humanized monoclonal antibody targeting circulating fibroblast growth factor 23 (FGF23), which has changed the landscape of XLH management, a panel of experts who spoke at EDM HK 2025 concurred.

X-linked hypophosphataemia: Multidisciplinary care needed, targeted therapy effectively normalizes phosphate homeostasis

Epilepsy risk elevated in children with congenital Zika syndrome

10 Dec 2025 by

New research suggests that in-utero exposure to Zika virus (ZIKV) alone does not increase the risk of epilepsy in early childhood, and the risk increase is limited to children who develop congenital Zika syndrome.

Epilepsy risk elevated in children with congenital Zika syndrome

Antimicrobial use rises following TNFi initiation in PsA patients

A recent study has noted a temporary increase in antimicrobial use following initiation of tumour necrosis factor inhibitor (TNFi) treatment, with no significant risk in serious infections, among patients with psoriatic arthritis (PsA).

Antimicrobial use rises following TNFi initiation in PsA patients

Whole foods, Mediterranean diet help improve endothelial function

10 Dec 2025 by

Eating whole foods such as fruits and vegetables regularly, as well as following a Mediterranean diet, can enhance endothelial function as measured by flow-mediated dilation (FMD), suggests a study.

Whole foods, Mediterranean diet help improve endothelial function